Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities

Benzinga_recent_news01-12

Immix Biopharma Inc (NASDAQ:IMMX) shares are trading marginally lower Monday morning after the clinical-stage biotech filed a new shelf registration statement on Form S-3 with the U.S. Securities and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603544343?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/12/Blue-Candlestick-Stock-Chart-With-Market.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-01-12 23:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603544343","market":"sh","top_or_hot":-1,"title":"Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities","media":"Benzinga_recent_news","content":"<div>\n<p>Immix Biopharma Inc (NASDAQ:IMMX) shares are trading marginally lower Monday morning after the clinical-stage biotech filed a new shelf registration statement on Form S-3 with the U.S. Securities and ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/01/49848420/immix-biopharma-immx-shares-slip-as-investors-focus-on-plans-to-offer-and-sell-750-million-in-securities\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-12 23:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/01/49848420/immix-biopharma-immx-shares-slip-as-investors-focus-on-plans-to-offer-and-sell-750-million-in-securities><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immix Biopharma Inc (NASDAQ:IMMX) shares are trading marginally lower Monday morning after the clinical-stage biotech filed a new shelf registration statement on Form S-3 with the U.S. Securities and ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/01/49848420/immix-biopharma-immx-shares-slip-as-investors-focus-on-plans-to-offer-and-sell-750-million-in-securities\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISBC","symbol_name":"投资者银行","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49848420/immix-biopharma-immx-shares-slip-as-investors-focus-on-plans-to-offer-and-sell-750-million-in-securities","article_id":"2603544343","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/12/Blue-Candlestick-Stock-Chart-With-Market.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49848420/immix-biopharma-immx-shares-slip-as-investors-focus-on-plans-to-offer-and-sell-750-million-in-securities","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603544343","pubTimestamp":1768232880,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Immix Biopharma Inc (NASDAQ: IMMX) shares are trading lower Monday after the company filed a new shelf registration statement.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ISBC":"投资者银行","BK4211":"区域性银行","BK4139":"生物科技","IMMX":"Immix Biopharma, Inc"},"translate_title":"由于投资者关注发行和出售7.5亿美元证券的计划，Immix Biopharma(IMMX)股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1.5,"IMMX":1.5},"content_text":"Immix Biopharma Inc (NASDAQ:IMMX) shares are trading marginally lower Monday morning after the clinical-stage biotech filed a new shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission. \nThe filing would allow the company to offer and sell up to $750 million of common stock, preferred stock, debt securities, warrants and units from time to time.\nThe latest S-3 is structured as a replacement shelf under SEC Rule 415(a)(6), carrying forward unsold securities from a prior registration that was declared effective in January 2023.\nUnder the new shelf registration, Immix can access the capital markets opportunistically, with specific terms and pricing of any future offerings to be detailed in subsequent prospectus supplements.\nImmix Biopharma plans to use net proceeds primarily for working capital and general corporate purposes, which may include advancing its lead CAR-T candidate NXC-201 for AL amyloidosis and other serious diseases. \nThe company also highlighted standard risk factors and forward-looking statement disclosures, reminding investors that any future equity issuance under the shelf could dilute existing shareholders.\nBenzinga Edge Rankings: Benzinga Edge's proprietary rankings show Immix Biopharma with a strong Momentum score of 96.03, supported by positive short-, medium- and long-term price trends.\nIMMX Price Action: Immix Biopharma shares were down 4.11% at $4.67 at the time of publication on Monday, according to Benzinga Pro data.\nThe stock’s 52-week range of $1.34 to $7.73 highlights its volatility and potential for significant price swings. Currently, the price is well above the lower end of this range, which may provide a psychological support level for investors looking to enter or add to their positions.\nResistance is likely to be encountered around the $5.00 mark, where sellers may emerge to capitalize on any upward momentum. Should the stock manage to break through this resistance, it could pave the way for a test of higher levels, potentially approaching the recent highs near $7.73.\nThe overall technical outlook for Immix Biopharma remains cautiously optimistic, as the stock is trading well above its historical lows. Continued monitoring of volume and price action will be essential to gauge the strength of any potential recovery or further declines in the near term.\nImage: Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603544343","isCrawlerRequest":true}